Table of Contents Author Guidelines Submit a Manuscript
International Journal of Cell Biology
Volume 2013, Article ID 576383, 7 pages
http://dx.doi.org/10.1155/2013/576383
Review Article

The Innate Immune System in Alzheimer’s Disease

1Department of Neurology, New York University School of Medicine, Alexandria East River Science Park, 450 East 29th Street, Room 802, New York City, NY 10016, USA
2Psychiatry Department, New York University School of Medicine, Alexandria East River Science Park, 450 East 29th Street, Room 802, New York City, NY 10016, USA
3Physiology and Neuroscience Department, New York University School of Medicine, Alexandria East River Science Park, 450 East 29th Street, Room 802, New York City, NY 10016, USA
4King Abdulaziz University, School of Medicine, Jeddah, KAU 21589, Saudi Arabia
5Pathology, New York University School of Medicine, Alexandria East River Science Park, 450 East 29th Street, Room 802, New York City, NY 10016, USA

Received 24 May 2013; Accepted 9 September 2013

Academic Editor: Alessio Cardinale

Copyright © 2013 Allal Boutajangout and Thomas Wisniewski. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Prince, R. Bryce, and C. Ferri, “World Alzheimer Report 2011,” Alzheimer's Disease International, 2011. View at Google Scholar
  2. L. Bertram and R. E. Tanzi, “The genetics of Alzheimer's disease,” in Progress in Molecular Biology and Translational Science, vol. 107, pp. 79–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. P. G. Ridge, M. T. Ebbert, and J. S. Kauwe, “Genetics of Alzheimer's disease,” BioMed Research International, vol. 2013, Article ID 254954, 13 pages, 2013. View at Publisher · View at Google Scholar
  4. H. Potter and T. Wisniewski, “Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade,” International Journal of Alzheimer's Disease, vol. 2012, Article ID 489428, 9 pages, 2012. View at Publisher · View at Google Scholar
  5. P. B. Verghese, J. M. Castellano, and D. M. Holtzman, “Apolipoprotein E in Alzheimer's disease and other neurological disorders,” The Lancet Neurology, vol. 10, no. 3, pp. 241–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. D. E. Barnes and K. Yaffe, “The projected effect of risk factor reduction on Alzheimer's disease prevalence,” The Lancet Neurology, vol. 10, no. 9, pp. 819–828, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Guerreiro, A. Wojtas, J. Bras et al., “TREM2 variants in Alzheimer's disease,” The New England Journal of Medicine, vol. 368, no. 2, pp. 117–127, 2013. View at Publisher · View at Google Scholar
  8. H. Neumann and M. J. Daly, “Variant TREM2 as risk factor for Alzheimer's disease,” The New England Journal of Medicine, vol. 368, no. 2, pp. 182–184, 2013. View at Publisher · View at Google Scholar
  9. T. Jonsson, H. Stefansson, S. Steinberg et al., “Variant of TREM2 associated with the risk of Alzheimer's disease,” The New England Journal of Medicine, vol. 368, no. 2, pp. 107–116, 2013. View at Publisher · View at Google Scholar
  10. A. Bouchon, C. Hernández-Munain, M. Cella, and M. Colonna, “A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells,” The Journal of Experimental Medicine, vol. 194, no. 8, pp. 1111–1122, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. E.-N. N'Diaye, C. S. Branda, S. S. Branda et al., “TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria,” The Journal of Cell Biology, vol. 184, no. 2, pp. 215–223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. D. S. Arroyo, J. A. Soria, E. A. Gaviglio, M. C. Rodriguez-Galan, and P. Iribarren, “Toll-like receptors are key players in neurodegeneration,” International Immunopharmacology, vol. 11, no. 10, pp. 1415–1421, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. L. Hanke and T. Kielian, “Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential,” Clinical Science, vol. 121, no. 9, pp. 367–387, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Drouin-Ouellet and F. Cicchetti, “Inflammation and neurodegeneration: the story “retolled”,” Trends in Pharmacological Sciences, vol. 33, no. 10, pp. 542–551, 2012. View at Publisher · View at Google Scholar
  15. A. Bouchon, J. Dietrich, and M. Colonna, “Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes,” The Journal of Immunology, vol. 164, no. 10, pp. 4991–4995, 2000. View at Google Scholar · View at Scopus
  16. T. Jiang, J. T. Yu, X. C. Zhu, and L. Tan, “TREM2 in Alzheimer's disease,” Molecular Neurobiology, vol. 48, no. 1, pp. 180–185, 2013. View at Publisher · View at Google Scholar
  17. T. E. Golde, W. J. Streit, and P. Chakrabarty, “Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease,” Alzheimer's Research & Therapy, vol. 5, article 24, no. 3, 2013. View at Publisher · View at Google Scholar
  18. R. J. Guerreiro, E. Lohmann, J. M. Bras et al., “Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement,” JAMA Neurology, vol. 70, pp. 78–84, 2013. View at Google Scholar
  19. S. Frank, G. J. Burbach, M. Bonin et al., “TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice,” Glia, vol. 56, no. 13, pp. 1438–1447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Melchior, A. E. Garcia, B.-K. Hsiung et al., “Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: Implications for vaccine-based therapies for Alzheimer's disease,” ASN Neuro, vol. 2, no. 3, article e00037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Paloneva, T. Manninen, G. Christman et al., “Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype,” The American Journal of Human Genetics, vol. 71, no. 3, pp. 656–662, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Singaraja, “TREM2: a new risk factor for Alzheimer's disease,” Clinical Genetics, vol. 83, no. 6, pp. 525–526, 2013. View at Publisher · View at Google Scholar
  23. G. Sessa, P. Podini, M. Mariani et al., “Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia,” European Journal of Neuroscience, vol. 20, no. 10, pp. 2617–2628, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. Hamerman, J. R. Jarjoura, M. B. Humphrey, M. C. Nakamura, W. E. Seaman, and L. L. Lanier, “Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12,” The Journal of Immunology, vol. 177, no. 4, pp. 2051–2055, 2006. View at Google Scholar · View at Scopus
  25. I. R. Turnbull, S. Gilfillan, M. Cella et al., “Cutting edge: TREM-2 attenuates macrophage activation,” The Journal of Immunology, vol. 177, no. 6, pp. 3520–3524, 2006. View at Google Scholar · View at Scopus
  26. J. A. Hamerman, N. K. Tchao, C. A. Lowell, and L. L. Lanier, “Enhanced toll-like receptor responses in the absence of signaling adaptor DAP12,” Nature Immunology, vol. 6, no. 6, pp. 579–586, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. C. L. Hsieh, M. Koike, S. C. Spusta et al., “A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia,” Journal of Neurochemistry, vol. 109, no. 4, pp. 1144–1156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Takahashi, M. Prinz, M. Stagi, O. Chechneva, and H. Neumann, “TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis,” PLoS Medicine, vol. 4, no. 4, article e124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Piccio, C. Buonsanti, M. Mariani et al., “Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis,” European Journal of Immunology, vol. 37, no. 5, pp. 1290–1301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. R. J. Guerreiro, E. Lohmann, J. M. Bras et al., “Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement,” JAMA Neurology, vol. 70, no. 1, pp. 78–84, 2013. View at Publisher · View at Google Scholar
  31. J. Paloneva, M. Kestilä, J. Wu et al., “Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts,” Nature Genetics, vol. 25, no. 3, pp. 357–361, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Paloneva, T. Manninen, G. Christman et al., “Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype,” The American Journal of Human Genetics, vol. 71, no. 3, pp. 656–662, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Fenoglio, D. Galimberti, L. Piccio et al., “Absence of TREM2 polymorphisms in patients with Alzheimer's disease and frontotemporal lobar degeneration,” Neuroscience Letters, vol. 411, no. 2, pp. 133–137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Rademakers, M. Baker, A. M. Nicholson et al., “Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids,” Nature Genetics, vol. 44, no. 2, pp. 200–205, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. P. T. Nelson, I. Alafuzoff, E. H. Bigio et al., “Correlation of alzheimer disease neuropathologic changes with cognitive status: a review of the literature,” Journal of Neuropathology and Experimental Neurology, vol. 71, no. 5, pp. 362–381, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Blennow and H. Hampel, “CSF markers for incipient Alzheimer's disease,” The Lancet Neurology, vol. 2, no. 10, pp. 605–613, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Hampel, K. Buerger, R. Zinkowski et al., “Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study,” Archives of General Psychiatry, vol. 61, no. 1, pp. 95–102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. M. J. De Leon, S. Desanti, R. Zinkowski et al., “MRI and CSF studies in the early diagnosis of Alzheimer's disease,” Journal of Internal Medicine, vol. 256, no. 3, pp. 205–223, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Buerger, M. Ewers, T. Pirttilä et al., “CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease,” Brain, vol. 129, no. 11, pp. 3035–3041, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Andersson, K. Blennow, O. Almkvist et al., “Increasing CSF phospho-tau levels during cognitive decline and progression to dementia,” Neurobiology of Aging, vol. 29, no. 10, pp. 1466–1473, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Cruchaga, J. S. Kauwe, O. Harari et al., “GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease,” Neuron, vol. 78, pp. 256–268, 2013. View at Google Scholar
  42. C. Hashimoto, K. L. Hudson, and K. V. Anderson, “The toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein,” Cell, vol. 52, no. 2, pp. 269–279, 1988. View at Google Scholar · View at Scopus
  43. R. Medzhitov, P. Preston-Hurlburt, and C. A. Janeway Jr., “A human homologue of the Drosophila toll protein signals activation of adaptive immunity,” Nature, vol. 388, no. 6640, pp. 394–397, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Lemaitre, E. Nicolas, L. Michaut, J.-M. Reichhart, and J. A. Hoffmann, “The dorsoventral regulatory gene cassette spatzle/toll/cactus controls the potent antifungal response in Drosophila adults,” Cell, vol. 86, no. 6, pp. 973–983, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Akira and K. Takeda, “Functions of toll-like receptors: lessons from KO mice,” Comptes Rendus, vol. 327, no. 6, pp. 581–589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Kawai and S. Akira, “TLR signaling,” Cell Death and Differentiation, vol. 13, no. 5, pp. 816–825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Kawai and S. Akira, “Toll-like receptor and RIG-1-like receptor signaling,” Annals of the New York Academy of Sciences, vol. 1143, pp. 1–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Kopp and R. Medzhitov, “Recognition of microbial infection by toll-like receptors,” Current Opinion in Immunology, vol. 15, no. 4, pp. 396–401, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Takeda, T. Kaisho, and S. Akira, “Toll-like receptors,” Annual Review of Immunology, vol. 21, pp. 335–376, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Kawai and S. Akira, “The role of pattern-recognition receptors in innate immunity: update on toll-like receptors,” Nature Immunology, vol. 11, no. 5, pp. 373–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. C. R. Stewart, L. M. Stuart, K. Wilkinson et al., “CD36 ligands promote sterile inflammation through assembly of a toll-like receptor 4 and 6 heterodimer,” Nature Immunology, vol. 11, no. 2, pp. 155–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Frank, E. Copanaki, G. J. Burbach, U. C. Müller, and T. Deller, “Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice,” Neuroscience Letters, vol. 453, no. 1, pp. 41–44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. G. E. Landreth and E. G. Reed-Geaghan, “Toll-like receptors in Alzheimer's disease,” Current Topics in Microbiology and Immunology, vol. 336, no. 1, pp. 137–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. M. V. Guillot-Sestier and T. Town, “Innate immunity in Alzheimer's disease: a complex affair,” CNS & Neurological Disorders, vol. 12, no. 5, pp. 593–607, 2013. View at Google Scholar
  55. T. Wyss-Coray, “Inflammation in Alzheimer disease: driving force, bystander or beneficial response?” Nature Medicine, vol. 12, no. 9, pp. 1005–1015, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Medzhitov and C. Janeway Jr., “The toll receptor family and microbial recognition,” Trends in Microbiology, vol. 8, no. 10, pp. 452–456, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Akira, “TLR signaling,” Current Topics in Microbiology and Immunology, vol. 311, pp. 1–16, 2006. View at Google Scholar
  58. K. Hoebe, E. Janssen, and B. Beutler, “The interface between innate and adaptive immunity,” Nature Immunology, vol. 5, no. 10, pp. 971–974, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Pasare and R. Medzhitov, “Toll-like receptors: balancing host resistance with immune tolerance,” Current Opinion in Immunology, vol. 15, no. 6, pp. 677–682, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. C. J. Hertz, S. M. Kiertscher, P. J. Godowski et al., “Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2,” The Journal of Immunology, vol. 166, no. 4, pp. 2444–2450, 2001. View at Google Scholar · View at Scopus
  61. A. Boonstra, C. Asselin-Paturel, M. Gilliet et al., “Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation,” The Journal of Experimental Medicine, vol. 197, no. 1, pp. 101–109, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Poltorak, X. He, I. Smirnova et al., “Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene,” Science, vol. 282, no. 5396, pp. 2085–2088, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. H. M. Kim, B. S. Park, J.-I. Kim et al., “Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran,” Cell, vol. 130, no. 5, pp. 906–917, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. S. M. Opal and C. T. Esmon, “Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis,” Critical Care, vol. 7, no. 1, pp. 23–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Aderem and R. J. Ulevitch, “Toll-like receptors in the induction of the innate immune response,” Nature, vol. 406, no. 6797, pp. 782–787, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Yu, L. Wang, M. Li, J. Zhong, Z. Wang, and S. Chen, “Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia,” Cancer Immunology, Immunotherapy, vol. 59, no. 7, pp. 1021–1028, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. D. Lagos, R. J. Vart, F. Gratrix et al., “Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus,” Cell Host and Microbe, vol. 4, no. 5, pp. 470–483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. M. G. Kelly, A. B. Alvero, R. Chen et al., “TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer,” Cancer Research, vol. 66, no. 7, pp. 3859–3868, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. W. He, Q. Liu, L. Wang, W. Chen, N. Li, and X. Cao, “TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance,” Molecular Immunology, vol. 44, no. 11, pp. 2850–2859, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. U. Kilic, E. Kilic, C. M. Matter, C. L. Bassetti, and D. M. Hermann, “TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration,” Neurobiology of Disease, vol. 31, no. 1, pp. 33–40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. A. M. Krieg, “CpG DNA: a pathogenic factor in systemic lupus erythematosus?” Journal of Clinical Immunology, vol. 15, no. 6, pp. 284–292, 1995. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Hemmi, O. Takeuchi, T. Kawai et al., “A toll-like receptor recognizes bacterial DNA,” Nature, vol. 408, no. 6813, pp. 740–745, 2000. View at Publisher · View at Google Scholar · View at Scopus
  73. P. Ahmad-Nejad, H. Hacker, M. Rutz, S. Bauer, R. M. Vabulas, and H. Wagner, “Bacterial CpG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments,” European Journal of Immunology, vol. 32, pp. 1958–1968, 2002. View at Google Scholar
  74. M. Letiembre, W. Hao, Y. Liu et al., “Innate immune receptor expression in normal brain aging,” Neuroscience, vol. 146, no. 1, pp. 248–254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. R. N. Aravalli, S. Hu, and J. R. Lokensgard, “Toll-like receptor 2 signaling is a mediator of apoptosis in herpes simplex virus-infected microglia,” Journal of Neuroinflammation, vol. 4, article 11, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. C. S. Jack, N. Arbour, J. Manusow et al., “TLR signaling tailors innate immune responses in human microglia and astrocytes,” The Journal of Immunology, vol. 175, no. 7, pp. 4320–4330, 2005. View at Google Scholar · View at Scopus
  77. H. Ito and J. A. Hamerman, “TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells,” European Journal of Immunology, vol. 42, no. 1, pp. 176–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Tahara, H.-D. Kim, J.-J. Jin, J. A. Maxwell, L. Li, and K.-I. Fukuchi, “Role of toll-like receptor signalling in Aβ uptake and clearance,” Brain, vol. 129, no. 11, pp. 3006–3019, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. B. Cameron and G. E. Landreth, “Inflammation, microglia, and alzheimer's disease,” Neurobiology of Disease, vol. 37, no. 3, pp. 503–509, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. Liu, S. Walter, M. Stagi et al., “LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide,” Brain, vol. 128, no. 8, pp. 1778–1789, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Fassbender, S. Walter, S. Kühl et al., “The LPS receptor (CD14) links innate immunity with Alzheimer's disease,” FASEB Journal, vol. 18, no. 1, pp. 203–205, 2004. View at Google Scholar · View at Scopus
  82. S. Walter, M. Letiembre, Y. Liu et al., “Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease,” Cellular Physiology and Biochemistry, vol. 20, no. 6, pp. 947–956, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. J.-J. Jin, H.-D. Kim, J. A. Maxwell, L. Li, and K.-I. Fukuchi, “Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease,” Journal of Neuroinflammation, vol. 5, article 23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. E. G. Reed-Geaghan, J. C. Savage, A. G. Hise, and G. E. Landreth, “CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation,” Journal of Neuroscience, vol. 29, no. 38, pp. 11982–11992, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. J. P. Michaud, M. Halle, A. Lampron et al., “Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 5, pp. 1941–1946, 2013. View at Publisher · View at Google Scholar
  86. A. Rolls, R. Shechter, A. London et al., “Toll-like receptors modulate adult hippocampal neurogenesis,” Nature Cell Biology, vol. 9, no. 9, pp. 1081–1088, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. Doi, T. Mizuno, Y. Maki et al., “Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid β neurotoxicity in in vitro and in vivo models of Alzheimer's disease,” American Journal of Pathology, vol. 175, no. 5, pp. 2121–2132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Scholtzova, R. J. Kascsak, K. A. Bates et al., “Induction of toll-like receptor 9 signaling as a method for ameliorating alzheimer's disease-related pathology,” Journal of Neuroscience, vol. 29, no. 6, pp. 1846–1854, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. D. S. Spinner, R. B. Kascsak, G. LaFauci et al., “CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils,” Journal of Leukocyte Biology, vol. 81, no. 6, pp. 1374–1385, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. A. M. Krieg, “Therapeutic potential of toll-like receptor 9 activation,” Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 471–484, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Bodera, W. Stankiewicz, and J. Kocik, “Synthetic immunostimulatory oligonucleotides in experimental and clinical practice,” Pharmacological Reports, vol. 64, pp. 1003–1010, 2012. View at Google Scholar
  92. H. Scholtzova, F. Goni, J. Pan, Y. Sun, P. Mehta, and T. Wisniewski, “Innate immunity stimulation as a novel therapeutic approach in Alzheimer's disease,” Alzheimer's & Dementia, vol. 8, no. 4, p. 392, 2012. View at Publisher · View at Google Scholar
  93. H. M. Wisniewski, J. Wegiel, K. C. Wang, and B. Lach, “Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease,” Acta Neuropathologica, vol. 84, no. 2, pp. 117–127, 1992. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Frackowiak, H. M. Wisniewski, J. Wegiel, G. S. Merz, K. Iqbal, and K. C. Wang, “Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce β-amyloid fibrils,” Acta Neuropathologica, vol. 84, no. 3, pp. 225–233, 1992. View at Google Scholar · View at Scopus
  95. H. M. Wisniewski and J. Wegiel, “The role of microglia in amyloid fibril formation,” Neuropathology and Applied Neurobiology, vol. 20, no. 2, pp. 192–194, 1994. View at Google Scholar · View at Scopus
  96. H. Shi, O. Belbin, C. Medway et al., “Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS),” Neurobiology of Aging, vol. 33, no. 8, pp. 1849.e5–1849.e18, 2012. View at Publisher · View at Google Scholar · View at Scopus